文献速递血栓与止血

Concizumab:一种新型抗TFPI的血友病治疗药物

Concizumab: a novel anti-TFPI therapeutic for hemophilia.
PubMed 文献 · Blood Adv · 2021-01-01

Concizumab是一种皮下预防性血友病治疗药物,通过结合组织因子途径抑制物(TFPI)的Kunitz-2结构域,阻止TFPI与凝血因子Xa(FXa)活性位点结合,从而促进止血。2项2期试验显示其安全性良好,无死亡、血栓栓塞事件或导致停药的不良事件,且在抑制剂患者中相比按需治疗显著降低年化出血率。基于2期结果,FDA授予其用于伴抑制剂血友病B的突破性疗法认定。

要点

  • Concizumab通过阻断TFPI恢复FXa生成,对血友病A和B及抑制剂状态均预期有效。
  • 2期试验显示安全性良好,无死亡、血栓栓塞或导致停药的不良事件。
  • 抑制剂患者中相比按需治疗,年化出血率显著且临床相关降低。

核心结论

  • Concizumab机制上对血友病A和B及抑制剂状态预期同等有效,2期试验证实安全性良好并显著降低抑制剂患者出血率。

研究设计与样本

  • 2项2期试验纳入伴或不伴抑制剂的血友病A或B患者。
  • 正在进行的3期试验将在伴或不伴抑制剂的血友病A或B患者中采用优化剂量方案。

主要发现

  • 2期试验显示无死亡、无血栓栓塞事件、无导致停药的不良事件。
  • 在所有评估的血友病亚型中证实预防出血的临床概念验证。
  • 抑制剂患者相比按需治疗,年化出血率显著且临床相关降低。

关键数值与推荐

  • Concizumab结合TFPI的Kunitz-2结构域,阻止TFPI与FXa活性位点结合。
  • TFPI抑制活性降低后,FVIIa-组织因子复合物产生足够FXa以实现止血。
  • FDA授予concizumab用于伴抑制剂血友病B的突破性疗法认定。

临床怎么用

  • Concizumab为皮下预防性治疗,机制上不干扰TFPI下游的凝血调控。
  • 基于2期结果,抑制剂患者中预防出血获益显著,尤其伴抑制剂血友病B为高未满足需求亚组。

局限性

  • 原文未报告2期试验的具体样本量、出血率数值、置信区间及P值。
  • 3期试验尚在进行中,优化剂量方案的有效性和安全性尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Concizumab is a novel subcutaneous prophylactic therapy for hemophilia. It is a hemostatic rebalancing agent that binds to the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), one of the molecules that contributes to downregulation of coagulation thereby preventing TFPI from binding to and blocking the factor Xa (FXa) active site. When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis. On the basis of this mechanism of action, concizumab is expected to be equally effective in hemophilia A and B, regardless of inhibitor status. Moreover, the concizumab mechanism of action does not interfere with the regulation of coagulation downstream of TFPI. Results from 2 phase 2 trials in patients with hemophilia A or B with and without inhibitors demonstrated that concizumab had a favorable safety profile, with no deaths, no thromboembolic events, and no adverse events leading to withdrawal. Clinical proof of concept in prevention of bleeding episodes was confirmed in both concizumab phase 2 trials across all hemophilia subtypes assessed, with a statistically significant and clinically relevant reduction in annualized bleeding rates observed in inhibitor patients compared to those who received on-demand treatment. On the basis of phase 2 results, the US Food and Drug Administration granted concizumab Breakthrough Therapy designation for hemophilia B with inhibitor patients, a rare and vulnerable patient subgroup that currently has the highest unmet medical need. In the ongoing concizumab phase 3 trials, an optimized dosing regimen will be administered in patients with hemophilia A or B with and without inhibitors.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv. 2021. PMID: 33570646. doi:10.1182/bloodadvances.2019001140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。